Sorrento therapeutics, inc. (SRNE)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenues:
Revenues

33,010

31,432

25,327

23,654

21,090

21,193

136,174

136,734

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant

-

-

-

-

-

-

-

-

-

-

-

-

705

-

1,365

1,590

1,721

1,530

1,223

1,003

628

488

422

358

416

452

481

532

607

584

589

546

403

329

299

263

0

0

0

Royalty and license

-

-

-

-

-

-

-

-

-

-

-

-

6,421

-

1,560

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales and services

-

-

-

-

-

-

-

-

-

-

-

-

4,912

-

2,545

2,715

2,867

3,060

2,828

3,221

3,198

3,337

2,698

1,569

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Collaboration

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Collaboration and reimbursable research and development costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

200

216

216

0

0

0

Total revenues

-

-

-

-

-

-

-

-

-

-

-

-

12,038

-

5,470

4,330

4,601

4,590

4,051

4,224

3,826

3,825

3,128

1,935

1,302

460

481

532

607

584

589

546

403

529

515

480

0

0

0

Operating costs and expenses:
Cost of products sold and services

-

-

-

10,112

-

-

-

4,602

4,192

-

2,704

2,037

1,516

811

1,595

1,781

1,800

1,950

1,870

1,793

1,989

2,043

1,600

1,073

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Research and development

102,417

106,879

102,787

94,781

87,947

76,963

64,990

62,027

55,281

55,532

55,938

49,716

49,281

42,175

37,191

34,053

31,280

31,343

30,182

28,378

25,716

23,983

18,938

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

0

0

-

-

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Acquired in-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69,013

37,013

24,013

24,068

0

0

-

0

-

-

-

-

0

0

-

3,376

3,061

2,780

2,570

2,207

1,884

0

0

0

Acquired in-process research and development

-

-

-

-

0

-

-

-

-

-

-

0

0

-

0

-

-

-

-

-

-

-

-

0

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Selling, general and administrative

0

-

-

-

0

-

-

-

36,406

38,332

41,430

36,483

31,611

24,219

24,112

23,556

22,408

20,132

12,389

9,532

8,821

9,987

10,045

9,305

8,452

6,317

4,587

3,900

2,637

1,606

1,072

804

1,087

1,201

1,232

1,393

0

0

0

Intangible amortization

3,941

3,941

4,018

3,682

3,347

3,009

2,636

2,637

2,645

2,610

2,459

1,915

1,361

845

445

444

682

1,157

1,633

2,108

2,345

2,345

1,952

1,366

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

Loss on contingent liabilities and acquisition consideration payable

-

-

-3,949

-3,953

-

-

22,254

17,753

12,687

-

-10,496

-7,715

-5,842

-8,121

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total operating costs and expenses

212,396

290,825

293,742

286,693

262,139

171,618

178,293

151,274

137,113

126,521

93,137

82,636

110,127

104,929

102,105

124,351

90,443

78,595

70,142

41,811

38,871

38,567

31,413

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Total operating costs and expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

Total expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

4,448

3,866

3,867

3,771

3,440

3,277

0

0

0

Loss from operations

-179,386

-259,393

-268,415

-263,039

-241,049

-150,425

-143,622

1,202

16,115

25,335

42,331

-66,835

-98,089

-96,777

-96,635

-120,021

-85,842

-74,005

-66,091

-37,587

-35,045

-34,742

-36,126

-32,302

-29,028

-21,668

-12,294

-10,230

-6,458

-4,852

-3,859

-3,319

-3,463

-3,242

-2,924

-2,797

0

0

0

(Loss) gain on trading securities

-356

-203

-229

-129

0

-

0

0

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on partial debt settlement

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Trading Securities, Realized Gain (Loss)

-

-

-

-

-

-

-

-

0

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on trading securities

-

-

-

-

-

-

-

-

-

-

-

-

0

-

0

0

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of IgDraSol, net

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on derivative liabilities

-17,399

-36,800

-32,962

-22,262

-11,671

2,830

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) gain on foreign currency exchange

-790

-330

-1,311

-772

-947

-1,243

-514

-747

-161

-178

-215

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense

33,884

36,139

36,945

30,170

65,659

57,631

49,708

48,232

4,423

4,980

4,811

3,839

2,912

1,610

1,191

1,351

1,520

1,652

1,739

1,819

1,845

1,629

1,337

912

466

253

0

0

0

-

-

-

-

-

-

-

-

-

-

Interest income

576

1,091

1,713

1,750

1,451

921

278

-206

20

241

380

671

484

272

107

82

37

24

2

3

8

12

15

15

12

10

7

7

7

7

6

5

5

5

5

4

0

0

0

Loss before income tax

-

-

0

0

-

-

0

0

0

-

37,138

-43,097

-72,532

-

-67,904

-49,885

-16,390

-9,719

4,048

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before income tax

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax benefit

-573

-473

-3,974

-4,574

-5,574

-6,274

-93,524

-35,244

-35,242

-36,038

53,685

-3,990

-2,592

-896

0

0

0

-

-

-1,897

-1,880

-1,702

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on equity method investments

-3,568

-3,909

-4,994

-4,463

-4,994

-5,019

-5,594

-41,221

-40,218

-40,244

0

0

0

-

-

-4,070

-4,540

-4,041

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain (loss) on equity investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-285,663

-363,012

-347,301

-322,543

-325,507

-212,526

-110,613

-58,706

1,364

11,109

-55,012

-40,722

-70,453

-63,937

-72,613

-90,435

-56,923

-50,074

-31,080

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to noncontrolling interests

-36,471

-70,944

-68,279

-60,608

-46,470

-8,986

-5,291

1,349

1,742

1,977

2,157

-1,504

-2,116

-3,014

-6,071

-7,064

-5,900

-4,263

-1,140

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to Sorrento

-249,192

-292,068

-279,022

-261,935

-279,037

-203,540

-105,322

-60,055

-378

9,132

-57,169

-39,218

-68,337

-60,923

-66,542

-83,371

-51,023

-45,811

-30,840

-37,506

-35,002

-34,657

-37,448

-33,199

-29,482

-21,911

-12,369

-10,254

-6,460

-4,845

-3,852

-3,313

-3,458

-3,236

-2,919

-2,792

0

0

0

Net loss per share - basic and diluted per share attributable to Sorrento (in dollars per share)

-

-

-

-

-

-

-

-

-

-

-

-0.20

-0.45

-

-

-

-

-

-

-0.30

-0.29

-0.26

-0.27

-0.33

-0.44

-0.67

-0.24

-0.35

-0.20

-0.24

-0.10

-0.08

0.00

-0.01

0.00

0.00

0.00

0.00

0.00

Weighted-average shares used during period - basic and diluted per share attributable to Sorrento (in shares)

-

-

-

-

-

-

-

-

-

-

-

70,302

50,886

-

-

-

-

-

-

36,315

36,206

78,134

28,533

25

23

20,294

14,135

13,443

12,312

-284,036

11,963

11,224

260,893

-

-

-

-

-

-

Net loss per share - basic per share attributable to Sorrento (USD per share)

-0.36

-0.37

-0.49

-0.46

-0.88

-0.41

-0.40

-0.73

-0.38

-

-0.03

-

-

-0.11

0.24

-0.93

-0.41

-

-0.03

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share - diluted per share attributable to Sorrento (USD per share)

-0.36

-0.50

-0.50

-0.47

-0.88

-0.41

-0.40

-0.73

-0.38

-

-0.03

-

-

-0.11

0.24

-0.93

-0.41

-

-0.03

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares used during period - basic per share attributable to Sorrento (in shares)

182,609

155,298

130,800

122,549

122,281

122,075

117,021

100,563

84,941

-

76,887

-

-

201,289

66

46

37

-

37

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares used during period - diluted per share attributable to Sorrento (in shares)

182,609

166,871

140,445

132,459

122,281

122,075

117,021

100,563

84,941

-

76,888

-

-

201,289

66

46

37

-

37

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted average number of shares during the period - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

250,348

247,686

247,256

246,902

230,300

219,836

Product
Revenues

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of products sold and services

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Service
Revenues

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of products sold and services

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Royalty and license
Total revenues

-

-

-

0

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Product And Service [Member]
Total revenues

-

-

-

0

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-